Atezolizumab Versus Atezolizumab Plus Bevacizumab as First Line in NSCLC Patients (BEAT)

This is a phase II controlled randomized study comparing atezolizumab as single agent to the combination of atezolizumab and bevacizumab in patients with chemonaive metastatic NSCLC with PD‐L1 expression. A total of maximum of 206 patients will be enrolled in the study. Patients will be treated with atezolizumab (1200 mg) every 3 weeks (6‐week cycles) or the combination of atezolizumab (1200 mg) every 3 weeks (6‐week cycles) plus bevacizumab (15 mg/kg) every 3 weeks until disease progression, unacceptable toxicity or patient refusal. Disease evaluation, along with various assessments, will be made every 3 weeks and every 6 weeks and follow‐up every 3 months. Toxicities will be evaluated throughout the study period. A follow‐up of 12 months is planned for each patient from the end of treatment .The study will be performed in approximately 20 centers across Italy.